Climb Bio (NASDAQ:CLYM – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank Of Canada in a report issued on Wednesday, Benzinga reports. They presently have a $23.00 price target on the stock. Royal Bank Of Canada‘s price target indicates a potential upside of 134.26% from the stock’s previous close.
CLYM has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating on shares of Climb Bio in a research report on Monday, October 12th. Oppenheimer boosted their price objective on shares of Climb Bio from $18.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, September 8th. Guggenheim reaffirmed a “buy” rating on shares of Climb Bio in a research note on Monday, October 26th. Wedbush increased their target price on shares of Climb Bio from $25.00 to $27.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Finally, Piper Sandler reissued an “overweight” rating on shares of Climb Bio in a research report on Tuesday, October 27th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $28.14.
View Our Latest Analysis on CLYM
Climb Bio Stock Up 0.4%
Climb Bio (NASDAQ:CLYM – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. As a group, equities research analysts expect that Climb Bio will post -0.75 earnings per share for the current year.
Insider Buying and Selling at Climb Bio
In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.
Institutional Trading of Climb Bio
Hedge funds have recently bought and sold shares of the stock. Braidwell LP grew its holdings in shares of Climb Bio by 102.6% during the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock worth $40,411,000 after buying an additional 1,569,352 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Climb Bio in the 2nd quarter valued at about $30,708,000. State Street Corp raised its stake in Climb Bio by 34.7% in the 3rd quarter. State Street Corp now owns 1,850,010 shares of the company’s stock valued at $21,220,000 after acquiring an additional 476,466 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Climb Bio during the 2nd quarter valued at $10,727,000. Finally, Integral Health Asset Management LLC acquired a new stake in Climb Bio during the 3rd quarter valued at $8,029,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.
Climb Bio Company Profile
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Featured Articles
- Five stocks we like better than Climb Bio
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
